DOACs in Renal Dysfunction and Liver Disease

The effectiveness, safety, and convenience of direct oral anticoagulants (DOACs) have made this class of medications the preferred anticoagulant in most cases. However, comorbid patients with significant renal or liver dysfunction were excluded from randomized controlled trials. As use of DOACs has proliferated, there has been increasing available data regarding DOACs in these special patient populations. Caution must still be exercised as these patient populations are at higher risk of both thrombotic and bleeding outcomes. This presentation will describe the available data in this realm and discuss an approach to determining which patients from these special populations may benefit the most from DOACs. This presentation was from Dr Allen Tran who presented it at the 2020 Thrombosis Canada Virtual Conference